WA-AGC-BIOLOGICS
24.1.2023 14:57:36 CET | Business Wire | Press release
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site. The CDMO is producing TZIELD™ (teplizumab-mzwv), a new T1D treatment from Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases.
Provention Bio chose AGC Biologics to manufacture TZIELD after the CDMO helped guide the product through PPQ manufacturing and validation batches, and United States Food and Drug Administration (FDA) approval. More than 1.8 million Americans have T1D, an autoimmune disease caused by the destruction of beta cells. TZIELD is the first and only immunomodulatory treatment that delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older. Patients who progress to Stage 3 T1D will eventually require insulin injections for life.
“The multi-year process of shepherding a new therapy from clinical research to commercial launch requires the collaboration of multiple partners, and we are grateful for the ongoing strategic collaboration of AGC Biologics as we begin to deliver TZIELD to patients,” said Provention Bio CEO Ashleigh Palmer. “This is an important milestone for the Type 1 Diabetes community, and we hope the launch of this therapy can truly make an impact on patients and families seeking innovative treatments for the delay of Stage 3 T1D.”
AGC Biologics runs multiple mammalian cGMP manufacturing lines and a variety of scales at its Seattle facility. The campus serves as a center of excellence for formulation and employs the latest fed-batch and perfusion manufacturing processes and houses a new microbial-based manufacturing line system. The AGC Biologics Seattle campus has produced biologics products for 30 years and has a long history of successful inspections by the FDA and commercial production.
“Congratulations to Provention Bio on this game-changing achievement for T1D patients,” said Kevin Ingham, General Manager of AGC Biologics’ Seattle site. “We at AGC Biologics are proud to have helped develop this innovative new medicine and to be manufacturing it for commercial distribution. This achievement demonstrates our Seattle site’s increasing track record in commercial manufacturing, which is aligned with AGC Biologic’s purpose of bringing hope to life.”
To learn more about AGC Biologics’ mammalian and microbial system-based biologics manufacturing site in Seattle, visit www.agcbio.com/facilities/seattle. For more information on the company’s Protein Biologics, Protein DNA (pDNA), Cell Therapy, Viral Vector and Messenger RNA (mRNA) drug product services visit www.agcbio.com.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including T1D, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005438/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Global Quality Program Marks 1,500 Green Glove Installer Engagements18.2.2026 12:00:00 CET | Press release
Continuous quality improvement produces better outcomes for solar customers with Green Glove installer support, and business process updates internally and in the field. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s vast network of solar installers has logged 1,500 Green Glove service program engagements. The Green Glove program helps reinforce the Company’s ongoing commitment to Total Quality Solar and deliver the best possible installer experience for participants, such as Brighthouse Solar of Central California. In addition to the Green Glove program, Tigo has deployed more than 12,000 customized onboarding sequences, across ten countries, to bring new installation companies up to speed on all things Tigo. From region-specific information to product and software training tips, these sequences are designed to ensure that installers have what they need based on their com
Battery Ventures Raises $3.25 Billion to Back Innovative Tech Companies Worldwide18.2.2026 10:00:00 CET | Press release
Battery—continuing to invest across the venture capital and buyout markets—has a single close on an oversubscribed fund Battery Ventures, the global, technology-focused investment firm, has closed a new, $3.25 billion fund to continue backing technology companies globally with a focus on the U.S., Europe and Israel. The new fund, Battery Ventures XV, comes on the heels of 15 announced exit events for the firm in 2025. Over the last five years Battery funds have realized more than $10 billion in liquidity, a testament to the firm’s stage-diversified approach. “We’re excited to build on our past success and partner with new, innovative companies in this dynamic market—driven, in large part, by the rise of artificial intelligence,” said Michael Brown, a Battery general partner. “To us, AI is ushering in one of the most consequential eras in the history of technology. We understand the gravity of this moment and feel well-suited to capitalize on the opportunity, given our global reach and
NICT Showcases Beyond 5G/6G Technologies at MWC Barcelona 202618.2.2026 09:00:00 CET | Press release
Japan's only national ICT research institute to present live demonstrations of terahertz-band wireless transmission, AI-driven communications, and advanced security technologies at Hall 6, Stand F54 National Institute of Information and Communications Technology (NICT), Japan’s leading public research organization in information and communications technology, today announced that it will exhibit at Mobile World Congress (MWC) Barcelona 2026, taking place from March 2–5, 2026, at Hall 6, Stand F54. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216620427/en/ NICT BOOTH NICT’s presence highlights Japan’s leadership in Beyond 5G and 6G research and development activities, addressing the growing limitations of current mobile networks as data traffic and connected devices continue to increase across Europe and globally. While 5G deployment is expanding, emerging applications such as AI-driven services, real-time analytics, and
BEYOND Developments Unveils EVERMORE Masterplan on Marjan Beach in Ras Al Khaimah18.2.2026 07:00:00 CET | Press release
BEYOND Developments unveiled EVERMORE, its first fully masterplanned destination on Marjan Beach in Ras Al Khaimah, marking the opening chapter of BEYOND’s 2026 growth strategy and a bold expansion beyond Dubai. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217969384/en/ EVERMORE by BEYOND Developments - The Essence of French Living at Marjan Beach, Ras Al Khaimah (Photo: AETOSWire) Strategically located opposite Wynn Al Marjan Island, EVERMORE is a long-term lifestyle and residential waterfront district framed by the sea and Marjan’s future botanical garden. The masterplan blends French classical elegance with contemporary architecture, integrated nature, and lifestyle-focused placemaking, creating a distinctive setting where architecture, hospitality, and public spaces harmonize with water and greenery. Mahdi Amjad, Founder and Executive Chairman of BEYOND Developments, said: “Ras Al Khaimah is witnessing a new phase o
Westlake Epoxy Expands Distribution Relationship with Brenntag to India18.2.2026 02:30:00 CET | Press release
Westlake Corporation (NYSE: WLK) today announced that Westlake Epoxy will expand its long‑standing distribution relationship with Brenntag to South and West India. The agreement builds on a successful collaboration across Europe, North and South America, and Southeast Asia, extending Westlake Epoxy’s reach into one of the world’s fastest‑growing coatings, adhesives and construction markets. Under the expanded collaboration, Brenntag will distribute Westlake Epoxy’s established portfolio of epoxy solutions for coatings, adhesives and construction applications, including the EPON™, EPIKOTE™, EPIKURE™ and EPI‑REZ™ product lines. Customers are expected to benefit from reliable local supply, technical service and application‑focused formulation support tailored to regional requirements. India’s coatings, adhesives and construction sectors continue to grow, driven by infrastructure investment, urbanization and increasing performance expectations. By combining Westlake Epoxy’s proven epoxy te
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom